Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $493000.0.

  • Janux Therapeutics' Cash from Financing Activities fell 7010.31% to $493000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $388.7 million, marking a year-over-year increase of 1870.25%. This contributed to the annual value of $713.2 million for FY2024, which is 109774.8% up from last year.
  • Per Janux Therapeutics' latest filing, its Cash from Financing Activities stood at $493000.0 for Q3 2025, which was down 7010.31% from $954000.0 recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Cash from Financing Activities peaked at $386.6 million during Q4 2024, and registered a low of -$843000.0 during Q3 2021.
  • Its 5-year average for Cash from Financing Activities is $64.5 million, with a median of $892500.0 in 2023.
  • As far as peak fluctuations go, Janux Therapeutics' Cash from Financing Activities crashed by 245454.55% in 2021, and later soared by 15790000.0% in 2023.
  • Quarter analysis of 5 years shows Janux Therapeutics' Cash from Financing Activities stood at $164000.0 in 2021, then rose by 16.46% to $191000.0 in 2022, then soared by 335.08% to $831000.0 in 2023, then skyrocketed by 46428.28% to $386.6 million in 2024, then tumbled by 99.87% to $493000.0 in 2025.
  • Its Cash from Financing Activities stands at $493000.0 for Q3 2025, versus $954000.0 for Q2 2025 and $554000.0 for Q1 2025.